Could an existing eczema drug help a rare skin condition?
NCT ID NCT04600362
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests dupilumab (Dupixent), an injectable drug already approved for atopic dermatitis, in 70 adults with nummular eczema, a chronic, itchy skin condition. Participants receive either dupilumab or a placebo for several weeks. The study measures changes in eczema severity and quality of life to see if the drug offers a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent), a monoclonal antibody injection
- What this could lead to
- If successful, this could provide a new treatment option for nummular eczema, reducing itching and improving skin appearance.
- What could go wrong
- This is an early Phase 2 trial with only 70 people. Dupilumab is already approved for other eczema types, but its effect on nummular eczema specifically is unproven, and side effects like injection reactions or infections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NUMMULAR ECZEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Klinikum re. Isar Dermatology
München, Bavaria, 81675, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.